---
title: "Avacta reports complete tumour responses in preclinical AVA6207 cancer studies"
publisher: "Share Talk"
author: "sharetalk"
published: "2026-11-19T07:30:58+00:00"
modified: "2026-11-19T07:30:58+00:00"
date: 2026-11-19
canonical: "https://www.share-talk.com/avacta-reports-complete-tumour-responses-in-preclinical-ava6207-cancer-studies/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["Abingdon Health", "AffyXell Therapeutics", "antigen", "Avacta Group", "AVCT", "Biotherapeutics", "Chris Yates", "Christina Coughlin", "clinical", "COVID-19", "Cytiva", "Daewoong Pharmaceutical", "diagnostic", "Doncaster", "Europe", "LG Chem Life Sciences", "Michelle Morrow", "Pharma", "radiopharmaceuticals", "saliva test", "SARS-COV-2", "Sengho Jeon", "Share Talk", "South Korea", "therapeutic", "UK", "validation", "York"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/11/e37e067b-805f-470a-9b7a-a0747e2d7f81.png?fit=1727%2C911&quality=80&ssl=1"
format: "news"
language: "en-GB"
---

# Avacta reports complete tumour responses in preclinical AVA6207 cancer studies

**Published:** November 19, 2026
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** Abingdon Health, AffyXell Therapeutics, antigen, Avacta Group, AVCT, Biotherapeutics, Chris Yates, Christina Coughlin, clinical, COVID-19, Cytiva, Daewoong Pharmaceutical, diagnostic, Doncaster, Europe, LG Chem Life Sciences, Michelle Morrow, Pharma, radiopharmaceuticals, saliva test, SARS-COV-2, Sengho Jeon, Share Talk, South Korea, therapeutic, UK, validation, York
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/11/e37e067b-805f-470a-9b7a-a0747e2d7f81.png?fit=1727%2C911&quality=80&ssl=1)

---

[Avacta Therapeutics (AIM: AVCT)](https://www.investegate.co.uk/announcement/rns/avacta-group--avct/ava6207-overcomes-top1i-resistance/9882905) has reported encouraging preclinical results for its experimental cancer treatment AVA6207, demonstrating the ability to overcome resistance to topoisomerase I inhibitors and achieve complete tumour responses in several animal models.

The life sciences company presented the findings on **19 November 2026 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona**, highlighting progress in its next-generation pre|CISION® drug development programme.

**AVA6207 combines two cancer-fighting agents, exatecan and berzosertib, within a single peptide-drug conjugate**, designed to release both compounds selectively within the tumour microenvironment.

Exatecan is a potent topoisomerase I inhibitor that damages cancer cell DNA, while berzosertib blocks the ATR kinase pathway used by cells to repair that damage.

By combining these mechanisms, Avacta aims to overcome resistance that can develop when tumours become less responsive to conventional topoisomerase I inhibitor treatments.

**The company’s proprietary pre|CISION technology uses fibroblast activation protein (FAP) to trigger the release of both drugs within the tumour environment**, potentially concentrating their activity at the intended treatment site.

The latest studies investigated two cancer characteristics associated with vulnerability to this approach: reduced expression of **SLFN11**, a protein involved in cellular responses to DNA damage, and loss of **ATM**, another important DNA repair regulator.

**Laboratory testing showed that AVA6207 reversed resistance in SLFN11-deficient cancer cells**, triggering extensive DNA damage and cell death.

In ATM-deficient cells, the treatment demonstrated **approximately tenfold greater sensitivity compared with ATM-positive or wild-type cells**, supporting the potential for a biomarker-led approach to patient selection.

The most notable findings came from patient-derived tumour models tested in animals.

**AVA6207 achieved complete responses in all animals carrying the tested SLFN11-low ovarian cancer tumours and in four out of five animals with ATM-low and SLFN11-low non-small cell lung cancer tumours.**

These results suggest strong activity against specific forms of treatment-resistant cancer, although complete responses in animal models do not establish that similar outcomes will occur in patients.

Avacta also reported that **AVA6207 outperformed the marketed antibody-drug conjugate Enhertu® in a separate gastric cancer model**.

The comparison provides additional preclinical evidence of activity but does not demonstrate superiority over Enhertu in human clinical treatment.

**Chief Executive Dr Christina Coughlin said resistance to topoisomerase I inhibitors remains a major challenge in cancer treatment**, particularly as the use of antibody-drug conjugates containing these compounds continues to expand.

She highlighted the complete responses in the ovarian and lung cancer models as encouraging evidence supporting AVA6207’s development in patients whose tumours have specific DNA repair vulnerabilities.

The findings also build on Avacta’s wider pre|CISION research programme, which includes **AVA6000 and AVA6103**.

**Avacta is evaluating colorectal, non-small cell lung, ovarian and oesophageal squamous cell cancers as potential clinical indications** for AVA6207.

The company intends to focus on patient populations with low SLFN11 expression or ATM deficiency, where the treatment’s dual mechanism may offer particular advantages.

This biomarker-defined approach could allow future clinical studies to concentrate on tumours considered more likely to respond, although the predictive value of these biomarkers will require validation in patients.

**AVA6207 is progressing towards investigational new drug (IND)-enabling studies during the fourth quarter of 2026**, following selection of its two therapeutic payloads.

These studies are intended to generate the safety, toxicology and manufacturing information required to support an application for human clinical testing.

**The treatment remains preclinical and has not yet demonstrated safety or efficacy in human patients.** Regulatory authorisation and successful clinical trials will be necessary before its therapeutic potential can be established.

For Avacta, the latest results provide further evidence supporting its strategy of using targeted drug delivery to improve the effectiveness of established cancer-fighting compounds while addressing treatment resistance.

**The next milestones will be completion of IND-enabling work, selection of priority clinical indications and progress towards first-in-human studies.**

The Barcelona presentation strengthens the scientific case for AVA6207, with **complete responses in selected animal models and increased sensitivity in ATM-deficient cells** providing promising early evidence for its dual-payload approach.

**The central question now is whether these preclinical findings can translate into meaningful clinical benefits for patients with cancers resistant to existing topoisomerase I inhibitor therapies.**

---

**Original URL:** https://www.share-talk.com/avacta-reports-complete-tumour-responses-in-preclinical-ava6207-cancer-studies/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*
